Eagle Pharmaceuticals, Inc.
Woodcliff Lake, NJ
- UEI
- VRQKPMHD3CK7
- CAGE
- 7LL94
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Active through
Company facts
- FY2025 rankings
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 50 Tice Blvd #315, Woodcliff Lake, NJ 07677, USA
- Website
- eagleus.com
- Founded
- 2007
- Employees
- 51-250
- Estimated annual revenue
- $10M-$50M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $180,293 |
| FY2025 | $395,395 |
| FY2024 | $238,095 |
| FY2023 | $499,829 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Defense Logistics Agency | $180,293 |
Contract vehicles
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Other medical | Medical Supply Chain (DLA) | $185,586 | |
| Ryanodex 250 MG vials | Medical Supply Chain (DLA) | $10,585 | |
| Ryanodex 250 MG vials | Medical Supply Chain (DLA) | $7,057 | |
| Dantrolene sodium f | Medical Supply Chain (DLA) | $5,293 | |
| Dantrolene sodium f | Medical Supply Chain (DLA) | $10,585 |
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| FKA West-Ward Pharmaceuticals | Berkeley Heights, NJ | 325412 Pharmaceutical Preparation Manufacturing |
| American Regent Inc. | Shirley, NY | 325412 Pharmaceutical Preparation Manufacturing |
| Janssen Pharmaceuticals, Inc. | Hopewell Township, NJ | 325412 Pharmaceutical Preparation Manufacturing |
| Amneal Pharmaceuticals Of New York, LLC | Medford, NY | 325412 Pharmaceutical Preparation Manufacturing |
| Chartwell RX LLC | Congers, NY | 325412 Pharmaceutical Preparation Manufacturing |
About the company
Eagle Pharmaceuticals, Inc., headquartered in Woodcliff Lake, New Jersey, manufactures critical injectable pharmaceuticals for the Department of Defense and Department of Veterans Affairs as a prime contractor, competing in the open market without set-aside designations. The company specializes in Ryanodex (dantrolene sodium) 250 mg vials and Dantrolene Sodium F, injectable medications used to treat and prevent malignant hyperthermia in high-risk patients during anesthesia, with all manufacturing performed at its Westwood, New Jersey facility.
Eagle operates as a for-profit manufacturer of goods under primary NAICS 325412 (Medicinal and Botanical Manufacturing), serving exclusively two federal customers across 259 recent prime awards valued at $46.1 million in combined potential value. The Defense Logistics Agency Troop Support Medical dominates by volume—256 awards carrying $9.2 million combined potential value—issuing nearly all work as short-cycle delivery orders and purchase orders for Ryanodex and Dantrolene Sodium vials averaging $4,500 to $10,000 per order. The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 12 anchors the dollar value with three awards worth $36.9 million combined potential value, centered on Eagle's $30.89 million Federal Supply Schedule contract (awarded February 1, 2024, running through January 31, 2029) covering drugs, pharmaceuticals, and hematology-related products under Federal Supply Classification 65 I B. That FSS contract enables both VISN 12 and the Defense Logistics Agency to procure on an as-needed basis.
Award activity patterns show concentration in 2023 (66 awards) followed by sharp decline—13 awards in 2022, 15 in 2024, 19 in 2025, and one order in early 2026. Only one award ($185,585.74 delivery order from February 2026) reaches ultimate completion within the next twenty-four months, signaling minimal recompete exposure in that window. The vast bulk of Eagle's recent work flows through Indefinite Delivery Contract SPE2D018D0006, a Defense Logistics Agency vehicle carrying 247 task orders worth $2.5 million combined potential value. Eagle holds no subcontracts and operates as a pure prime, with no joint venture or teaming relationships evident in the source. The company's Federal Supply Schedule position and recurring small-order pattern position it as the sole-source or primary supplier of these two highly specialized malignant hyperthermia medications to the federal medical supply chain, with pricing driven by firm fixed-price delivery-order competition on the open market rather than set-aside categories or volume-driven vehicles.
Quick answers
Is Eagle Pharmaceuticals, Inc. registered in SAM.gov?
Yes. Eagle Pharmaceuticals, Inc.'s SAM.gov registration is active through October 1, 2027.
Which contract vehicles does Eagle Pharmaceuticals, Inc. hold?
Eagle Pharmaceuticals, Inc. holds a place on 1 federal contract vehicle: FSS-61-IB.
How much has Eagle Pharmaceuticals, Inc. received in federal contracts?
Federal contracts obligated $395,395 to Eagle Pharmaceuticals, Inc. in fiscal year 2025 and $1,313,613 in fiscal years 2023 through 2027.
How does Eagle Pharmaceuticals, Inc. rank among federal contractors?
Eagle Pharmaceuticals, Inc. ranked #12 in NAICS 4242 and #20 in NAICS 325411 in FY2025.
What is Eagle Pharmaceuticals, Inc.'s most recent federal award?
Eagle Pharmaceuticals, Inc.'s most recent federal contract award is Other medical (SPE2D026F0105), from Medical Supply Chain (DLA), on February 26, 2026.
On GovTribe
See Eagle Pharmaceuticals, Inc.'s full federal record
- Federal contract awards
- IDV awards
- Contract vehicles
- Funding analysis by agency, NAICS and set-aside
- Similar vendors